Eli Lilly Says Milestone Payments Boost Potential Value of Ataibeckley Deal

Dow Jones07-16 19:07

Beyond the $6.75 per share upfront cash, Lilly is offering up to $2.50 per share through contingent value rights tied to specific milestones. The CVR represents a potential additional $1.0 billion in equity value. Payments hinge on development and regulatory progress: $1.00 per share if VLS-01 starts a Phase three trial within four years of closing, $0.50 per share upon U.S. approval and DEA rescheduling of BPL-003 within five years, and $1.00 per share upon U.S. approval and rescheduling of VLS-01 within seven years.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

July 16, 2026 07:07 ET (11:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment